

Effects of shokyo (*Zingiberis Rhizoma*) and kankyo (*Zingiberis Processum Rhizoma*) on prostaglandin E₂ production in lipopolysaccharide-treated mouse macrophage RAW264.7 cells

Toshiaki Ara^{Corresp.,1}, Hiroyuki Kitamura², Norio Sogawa¹

¹ Department of Pharmacology, Matsumoto Dental University, Shiojiri, Nagano, Japan

² Matsumoto Dental University Hospital, Shiojiri, Nagano, Japan

Corresponding Author: Toshiaki Ara
Email address: toshiaki.ara@mdu.ac.jp

We previously reported that shokyo and kankyo, which are water-extracted fractions of ginger, reduced LPS-induced PGE₂ production in human gingival fibroblasts. In this study, we examined the effects of these herbs on LPS-treated mouse macrophage RAW264.7 cells. Both shokyo and kankyo reduced LPS-induced PGE₂ production in a concentration-dependent manner, but the effects of kankyo were stronger than those of shokyo. Shokyo and kankyo did not inhibit cyclooxygenase (COX) activity, nor did they alter the expression of molecules in the arachidonic acid cascade. In addition, these herbs did not alter NF-κB p65 or ERK phosphorylation. These results suggest that shokyo and kankyo inhibit cPLA₂ activity. Although 6-shogaol produced similar results to those of shokyo and kankyo, the concentration of 6-shogaol required for the reduction of PGE₂ production were higher than those of 6-shogaol in shokyo and kankyo. Therefore, several gingerols and shogaols other than 6-shogaol may play a role in the reduction of LPS-induced PGE₂ production. Thus, 6-shogaol, and other gingerols and shogaols inhibit cPLA₂ activity and reduce LPS-induced PGE₂ production via a different mechanism from traditional anti-inflammatory drugs. Moreover, kampo medicines that contain shokyo or kankyo are considered to be effective for inflammatory diseases.

1 **Effects of shokyo (*Zingiberis Rhizoma*) and**
2 **kankyo (*Zingiberis Processum Rhizoma*) on**
3 **prostaglandin E₂ production in**
4 **lipopolysaccharide-treated mouse**
5 **macrophage RAW264.7 cells**

6 Toshiaki Ara¹, Hiroyuki Kitamura², and Norio Sogawa¹

7 ¹Department of Pharmacology, Matsumoto Dental University, 1780 Gobara Hirooka,
8 Shiojiri, Nagano 399-0781, Japan

9 ²Matsumoto Dental University Hospital, 1780 Gobara Hirooka, Shiojiri, Nagano
10 399-0781, Japan

11 Corresponding author:

12 Toshiaki Ara¹

13 Email address: toshiaki.ara@mdu.ac.jp

14 **ABSTRACT**

15 We previously reported that shokyo and kankyo, which are water-extracted fractions of gin-
16 ger, reduced LPS-induced PGE₂ production in human gingival fibroblasts. In this study, we
17 examined the effects of these herbs on LPS-treated mouse macrophage RAW264.7 cells.
18 Both shokyo and kankyo reduced LPS-induced PGE₂ production in a concentration-dependent
19 manner, but the effects of kankyo were stronger than those of shokyo. Shokyo and kankyo
20 did not inhibit cyclooxygenase (COX) activity, nor did they alter the expression of molecules
21 in the arachidonic acid cascade. In addition, these herbs did not alter NF-κB p65 or ERK
22 phosphorylation. These results suggest that shokyo and kankyo inhibit cPLA₂ activity. Al-
23 though 6-shogaol produced similar results to those of shokyo and kankyo, the concentration of
24 6-shogaol required for the reduction of PGE₂ production were higher than those of 6-shogaol in
25 shokyo and kankyo. Therefore, several gingerols and shogaols other than 6-shogaol may play
26 a role in the reduction of LPS-induced PGE₂ production. Thus, 6-shogaol, and other gingerols
27 and shogaols inhibit cPLA₂ activity and reduce LPS-induced PGE₂ production via a different
28 mechanism from traditional anti-inflammatory drugs. Moreover, kampo medicines that contain
29 shokyo or kankyo are considered to be effective for inflammatory diseases.

30 **INTRODUCTION**

31 Japanese traditional medicines (kampo medicines) are used for the treatment of several inflam-
32 matory diseases. We focused on the inflammatory effects of these kampo medicines, and found
33 that lipopolysaccharide (LPS)-induced PGE₂ production by human gingival fibroblasts (HGFs)
34 were reduced by several kampo medicines, including shosaikoto (TJ-9) (Ara et al., 2008), orento
35 (TJ-120) (Ara et al., 2010), hangeshashinto (TJ-14) (Nakazono et al., 2010), kakkonto (TJ-1)
36 (Kitamura et al., 2014), shinbuto (TJ-30), and ninjinto (TJ-32) (Ara and Sogawa, 2017). More-
37 over, among the herbs contained in kakkonto, shokyo (*Zingiberis Rhizoma*), kanzo (*Glycyrrhizae*
38 *Radix*), keihi (*Cinnamomi Cortex*) (Ara and Sogawa, 2016), and kankyo (*Zingiberis Processum*
39 *Rhizoma*) reduced PGE₂ production (Ara and Sogawa, 2017). In particular, shokyo and kankyo
40 strongly reduced LPS-induced PGE₂ production. These results suggested that kampo medicines

41 that include shokyo or kankyo have anti-inflammatory effects for periodontal disease.

42 Both shokyo and kankyo are contained in almost all kampo medicines, and are the aqueous
43 extracts of ginger (*Zingiber officinale* Roscoe). As described in the recent our review (Ara et al.,
44 2018), shokyo is the powdered rhizome of ginger, and kankyo is the steamed and powdered
45 rhizome of ginger. Many reports have demonstrated that ginger possesses anti-inflammatory
46 effects as below. Ginger is clinically used as a treatment for rheumatoid arthritis, fever, emesis,
47 nausea, and migraine headache (Afzal et al., 2001), and a systematic review revealed that the
48 extracts of ginger are clinically effective as hypoanalgesic agents (Lakhan et al., 2015). In
49 an animal model, oral- or intraperitoneal-administrated aqueous extract of ginger reduced the
50 serum PGE₂ level in rats (Thomson et al., 2002). Moreover, the crude hydroalcoholic extract of
51 ginger reduced LPS-induced PGE₂ serum level, and improved tracheal hyperreactivity and lung
52 inflammation in rats (Aimbire et al., 2007). Furthermore, ethanol extract of ginger reduced the
53 tissue level of PGE₂ and improved acetic acid-induced ulcerative colitis in rats (El-Abhar et al.,
54 2008).

55 Although there are many reports on hydrophobic solvent-extracts of ginger, as described
56 above, there are few reports on the effects of shokyo or kankyo (Thomson et al., 2002; Ara and
57 Sogawa, 2016, 2017). Therefore, we examined the effects of shokyo and kankyo themselves on
58 PGE₂ production and the arachidonic acid cascade in mouse macrophage RAW264.7 cells. We
59 also investigated the effects of 6-shogaol at a concentration corresponding to that of these herbs.

60 MATERIALS AND METHODS

61 Reagents and cells

62 Powders of shokyo and kankyo were provided by Tsumura & Co. These powders were suspended
63 in Dulbecco's modified Eagle's medium (D-MEM, Wako, Osaka, Japan) containing 10 % heat-
64 inactivated fetal calf serum, 100 units/ml of penicillin, and 100 mg/ml of streptomycin (culture
65 medium), and were rotated at 4 °C overnight. Then, the suspensions were centrifuged and the
66 supernatants were filtered through a 0.45 μm pore membrane. Lipopolysaccharide (LPS) from
67 *Porphyromonas gingivalis* 381 was provided by Professor Nobuhiro Hanada (School of Dental
68 Medicine, Tsurumi University, Japan). Arachidonic acid and 6-shogaol were purchased from
69 Cayman Chemical (Ann Arbor, MI). Other reagents were purchased from Nacalai Tesque.

70 The mouse macrophage cell line RAW264.7 (RIKEN BioResource Research Center, Tsukuba,
71 Japan) was cultured in culture medium at 37 °C in a humidified atmosphere of 5 % CO₂.

72 Measurement of cell viability

73 The numbers of viable cells were measured using WST-8 (Cell Counting Kit-8; Dojindo,
74 Kumamoto, Japan) according to the manufacturer's instructions. In brief, cells were seeded
75 onto 96-well plates (AGC Techno Glass Co., Chiba, Japan) (50000 cells/well), and treated with
76 shokyo or kankyo for 24 h. Then, the media were removed by aspiration and the cells were
77 treated with a 100 μl mixture of WST-8 with culture medium for 2 h at 37 °C in a CO₂ incubator.

78 The optical density was measured (measured wavelength at 450 nm and reference wavelength
79 at 655 nm) using an iMark microplate reader (Bio-Rad, Hercules, CA), and the mean background
80 value was subtracted from each value. Data are presented as mean ± SD (n = 4).

81 Measurement of prostaglandin E₂ (PGE₂)

82 RAW264.7 cells were seeded in 96-well plates (50000 cells/well) and incubated in culture
83 medium at 37 °C overnight. For simultaneous treatment, cells were treated with varying concen-
84 trations of each herb in the absence or presence of LPS (100 ng/ml) for 24 h (200 μl per well)
85 in triplicate or quadruplicate for each sample. For sequential treatment, cells were treated with
86 medium or LPS for 30 min, and thereafter treated with medium or each herb for 24 h. After

87 the culture supernatants were collected, viable cell numbers were measured using WST-8 as
88 described above.

89 The concentrations of PGE₂ in the culture supernatants were measured by enzyme-linked
90 immunosorbent assay (ELISA) according to the manufacturer's instructions (Cayman Chemical),
91 and were adjusted by the number of viable cells. Data are presented as pg per 10000 cells (mean
92 ± SD).

93 **Measurement of cyclooxygenase (COX)-2 activity**

94 COX-2 activity was evaluated as reported previously (Wilborn et al., 1995), with slight mod-
95 ification. In brief, to estimate COX-2 activity, RAW264.7 cells (50000 cells/well in 96-well
96 plate) were treated with LPS and each herb for 6 h (simultaneous treatment) or LPS for 6 h
97 and thereafter with each herb for 1 h (sequential treatment). Then, the cells were washed and
98 incubated in culture medium containing exogenous arachidonic acid (10 μM) for 30 min. The
99 concentrations of PGE₂ in the supernatants were measured by ELISA. Data are presented as pg
100 per 10000 cells (mean ± SD).

101 **Preparation of cell lysates**

102 RAW264.7 cells were cultured in 60-mm dishes, and treated with combinations of LPS and
103 herbs for the indicated times. Then, the cells were washed twice with Tris-buffered saline,
104 transferred into microcentrifuge tubes, and centrifuged at 6000 × g for 5 min at 4 °C. Super-
105 natants were aspirated and cells were lysed on ice in lysis buffer [50 mM Tris-HCl, pH 7.4,
106 1 % Nonidet P-40, 0.25 % sodium deoxycholate, 150 mM NaCl, 1 mM ethyleneglycol bis(2-
107 aminoethylether)tetraacetic acid (EGTA), 1 mM sodium orthovanadate, 10 mM sodium fluoride,
108 1/100 volume of protease inhibitor cocktail (Nacalai tesque), and 1/100 volume of phosphatase
109 inhibitor cocktail (Nacalai tesque)] for 30 min at 4 °C. Samples were next centrifuged at 12000
110 × g for 15 min at 4 °C, and supernatants were collected. The protein concentration was measured
111 using a BCA Protein Assay Reagent kit (Pierce Chemical Co., Rockford, IL).

112 **Western blotting**

113 The samples (50 μg of protein) were fractionated in a polyacrylamide gel under reducing con-
114 ditions and transferred onto a polyvinylidene difluoride (PVDF) membrane (Hybond-P; GE
115 Healthcare, Uppsala, Sweden). The membranes were blocked with 5 % ovalbumin for 1 h at room
116 temperature and incubated with the primary antibody for an additional 1 h. The membranes were
117 further incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room
118 temperature. Protein bands were visualized with an ECL kit (GE Healthcare). Densitometric
119 values of each band were calculated using ImageJ software.

120 Antibodies against COX-2 (sc-1745, 1:500 dilution), cytosolic PLA₂ (cPLA₂) (sc-438, 1:200
121 dilution), LOX-5 (LO-5, sc-515821, 1:250 dilution), annexin 1 (sc-11387, 1:1000 dilution),
122 actin (sc-1616, 1:1000 dilution), NF-κB p65 (sc-372, 1:1000 dilution), and phosphorylated
123 p65 (Ser536) (p-NF-κB p65; sc-101752, 1:200 dilution) were purchased from Santa Cruz
124 Biotechnology (Santa Cruz, CA). Antibodies against extracellular signal-regulated kinase (ERK;
125 p44/42 MAP kinase antibody, 1:1000 dilution) and phosphorylated ERK [Phospho-p44/42
126 MAPK (Thr202/Tyr204) (E10) monoclonal antibody, 1:2000 dilution] were from Cell Signaling
127 Technology (Danvers, MA). Horseradish peroxidase-conjugated anti-goat IgG (sc-2020, 1:20000
128 dilution) was from Santa Cruz, and anti-rabbit IgG (1:20000 dilution) and anti-mouse IgG
129 (1:20000 dilution) were from DakoCytomation (Glostrup, Denmark).

130 **Quantification of 6-shogaol in shokyo and kankyo**

131 The quantification of 6-shogaol in each herb was performed by the Nagano Prefecture Pharma-
132 ceutical Association Analytical Examination Center (Nagano, Japan). In brief, 1 ml of samples

133 (herbs in culture medium) was absorbed to a reverse-phase system cartridge (SepPak tC18,
134 Waters, Milford, MA). Columns were washed with 2 ml of 40 % MeOH and 1 ml of 70 % MeOH.
135 Then, samples were eluted with 100 % MeOH and concentrated to 1 ml. These samples were
136 subjected to high-performance liquid chromatography (HPLC) with LC-20A (SHIMADZU,
137 Kyoto, Japan). The conditions were as follows: column, X-Bridge 2.1 × 150 mm, 3 μm (Wa-
138 ters); solvent, 70 % aqueous acetonitrile; flow rate, 0.15 min/ml; column oven, 40 °C; detection,
139 228 nm; and injection, 10 μl.

140 **Statistical analysis**

141 Differences between the control group and experimental groups were evaluated by a two-tailed
142 Dunnett's test. All computations were performed with the statistical program R (R Development
143 Core Team, 2018). Dunnett's test was performed using the 'glht' function in the 'multcomp'
144 package (Hothorn et al., 2008). The IC₅₀ value and its 95 % confidence interval (CI) were
145 calculated using the 'drm' function in the 'drc' package (Ritz et al., 2015). Values with $P < 0.05$
146 were considered significantly different.

147 **RESULTS**

148 **Effects of shokyo and kankyo on cell viability**

149 We first examined the effects of shokyo and kankyo on RAW264.7 cell viability. Both shokyo
150 and kankyo reduced the cell viability in a concentration-dependent manner (Figure 1A and 1B).
151 These effects were significant but weak at 1000 μg/ml, demonstrating that shokyo and kankyo
152 have low cytotoxicity. Therefore, concentrations up to 100 μg/ml of shokyo and kankyo were
153 used in further experiments because we used the same concentration of herbs in previous studies
154 (Ara and Sogawa, 2016, 2017).

155 **Effects of shokyo and kankyo on prostaglandin E₂ (PGE₂) production**

156 We next examined whether shokyo and kankyo affect the production of PGE₂ by RAW264.7 cells.
157 The time schedule of treatment is shown in Figure 2A. In the simultaneous treatment experiment,
158 RAW264.7 cells treated with 100 ng/ml of LPS produced PGE₂. Shokyo and kankyo (both
159 100 μg/ml) strongly reduced LPS-induced PGE₂ production (Figure 2B), and the effects of
160 kankyo were stronger than those of shokyo.

161 To exclude the possibility that components in these herbs non-specifically bind the LPS
162 receptor and inhibit LPS signaling, we performed a sequential treatment experiment. In this
163 experiment, the cells were treated with LPS first, and the LPS receptor was not inhibited. The
164 same results (Figure 2C) as in the simultaneous treatment experiment were obtained, suggesting
165 that the reduction of PGE₂ production is due to non-specific binding of the LPS receptor by
166 components in shokyo and kankyo. Therefore, we performed simultaneous treatment in the
167 following experiments.

168 We investigated the concentration-dependent effects of shokyo and kankyo on LPS-induced
169 PGE₂ production. Both herbs reduced LPS-induced PGE₂ production in a concentration-
170 dependent manner (Figure 2D and 2E).

171 We also examined leukotriene B₄ (LTB₄) production, but we were unable to detect LTB₄
172 regardless of LPS treatment (data not shown).

173 **Effects of kankyo and shokyo on the arachidonic acid cascade**

174 To clarify the mechanism by which shokyo and kankyo reduce LPS-induced PGE₂ production
175 more directly, we assessed the effects of these two herbs on the arachidonic acid cascade. First,
176 we examined the effects of shokyo and kankyo on COX activity. In order to bypass PLA₂, we
177 added exogenous arachidonic acid to RAW264.7 cells treated with LPS alone or LPS plus herbs

178 (simultaneous treatment experiment). Then, we measured the PGE₂ level produced by COX.
179 Both shokyo and kankyo increased LPS-induced PGE₂ production (Figure 3B), suggesting that
180 these two herbs increase COX-2 activity. Next, to exclude the effects of the change in COX-2
181 expression, we performed the sequential treatment experiment. As the cells were treated with
182 LPS first in this experiment, COX-2 protein levels were considered to be comparable. Kankyo
183 slightly increased LPS-induced PGE₂ production (Figure 3C). Based on these results, shokyo
184 and kankyo do not inhibit COX-2 activity.

185 Next, we examined whether shokyo and kankyo affect the expression of molecules in the
186 arachidonic acid cascade. Shokyo and kankyo slightly reduced cPLA₂ expression (Figure 3D).
187 COX-2 was not expressed in the absence of LPS, and the treatment with LPS alone increased
188 COX-2 expression. Shokyo and kankyo did not alter LPS-induced COX-2 expression (Figure
189 3D). Moreover, shokyo and kankyo did not alter annexin 1 expression (Figure 3D).

190 The expression of COX-2 is well known to be regulated by NF-κB. Therefore, we analyzed
191 NF-κB activation by the level of phosphorylation of p65, a subunit of NF-κB. Phosphorylated
192 p65 (p-p65) was not detected without LPS treatment, and treatment with LPS alone increased
193 the p-p65 level. Pretreatment of shokyo or kankyo for 1 h did not alter LPS-induced p65
194 phosphorylation (Figure 3E), demonstrating that shokyo and kankyo did not inhibit NF-κB
195 activity.

196 Moreover, we evaluated the effects of shokyo and kankyo on ERK phosphorylation. cPLA₂
197 is directly phosphorylated and activated by phosphorylated ERK (Lin et al., 1993; Gijón et al.,
198 1999). Therefore, we examined whether shokyo and kankyo suppress LPS-induced ERK phos-
199 phorylation. LPS treatment increased ERK phosphorylation at 0.5 h and its phosphorylation was
200 later attenuated. However, 100 μg/ml of shokyo or kankyo only slightly reduced LPS-induced
201 ERK phosphorylation (Figure 3F).

202 We also evaluated the effects of shokyo and kankyo on the lipoxygenase pathway. Lipoxy-
203 genase (LOX)-5 expression was not altered by LPS treatment. Moreover, LOX-5 expression
204 was not affected by shokyo or kankyo (Supplemental Figure 1A). Shokyo and kankyo did not
205 change LOX activity because LTB₄ production was not altered when arachidonic acid was added
206 (Supplemental Figure 1B and 1C). Furthermore, the LTB₄ level was lower than that of PGE₂
207 (Figure 3B and 3C).

208 **Quantification of 6-shogaol in shokyo and kankyo**

209 6-Shogaol is one of the major and bioactive components in shokyo and kankyo. In order to assess
210 the effects of 6-shogaol on PGE₂ production by RAW264.7 cells at a similar concentration to
211 shokyo and kankyo, we quantified the amount of 6-shogaol in shokyo and kankyo. HPLC analysis
212 revealed that the 5 mg/ml shokyo and kankyo solutions used in this study contained 2.97 μM
213 and 4.87 μM 6-shogaol, respectively (Table 1 and Supplemental Figure 2). Thus, 100 μg/ml of
214 shokyo and kankyo contained 59.4 nM and 97.4 nM 6-shogaol, respectively (Table 1).

215 **Effects of 6-shogaol on PGE₂ production and molecular expression in the arachi- 216 donic acid cascade**

217 We investigated the effects of 6-shogaol on LPS-induced PGE₂ production by RAW264.7 cells.
218 6-Shogaol reduced LPS-induced PGE₂ production in a concentration-dependent manner (Figure
219 4A). One hundred nM 6-shogaol reduced PGE₂ production to approximately 50 %, and 1000 nM
220 (= 1 μM) 6-shogaol inhibited PGE₂ production. The IC₅₀ value of 6-shogaol was 105 nM (95 %
221 CI: 27.7–182 nM). However, the effects of 6-shogaol were weaker than those of shokyo and
222 kankyo considering the concentration of 6-shogaol in shokyo and kankyo (red and blue lines in
223 Figure 4A).

224 The effects of 6-shogaol on the expression of molecules in the arachidonic acid cascade

225 and intracellular signal transduction pathways were evaluated, but 10 μM 6-shogaol did not
226 affect the expression of cPLA₂, annexin 1, or COX-2 (Figure 4B). Similarly, 6-shogaol did not
227 affect NF- κ B p65 phosphorylation (Figure 4C). In contrast, 6-shogaol slightly reduced ERK
228 phosphorylation (Figure 4D).

229 DISCUSSION

230 There are few reports on the effects of shokyo or kankyo, which are aqueous extracts of ginger.
231 We previously examined the effects of shokyo and kankyo on the arachidonic acid cascade in
232 HGFs, and suggested that these herbs inhibit cPLA₂ activity because they did not inhibit COX-2
233 activity or suppress cPLA₂ and COX-2 expression (Ara and Sogawa, 2016, 2017). In this study,
234 we examined the effects of these herbs in macrophage-like RAW264.7 cells and obtained similar
235 results (Figure 3B–3D). In addition, shokyo and kankyo did not alter annexin 1 (also named
236 lipocortin1) expression (Figure 3D), which is produced by glucocorticoids and inhibits cPLA₂
237 activity (Gupta et al., 1984; Wallner et al., 1986). Moreover, shokyo and kankyo did not alter
238 NF- κ B phosphorylation (Figure 3E), which is required to induce COX-2 expression and ERK
239 phosphorylation (Figure 3F), which leads to the activation of cPLA₂. These results suggest that
240 shokyo and kankyo inhibit cPLA₂ activity in RAW264.7 cells and in HGFs, and their effects
241 may be cell type-non-specific.

242 As a possible mechanism by which shokyo and kankyo reduced LPS-induced PGE₂ pro-
243 duction, components of shokyo and kankyo may bind to LPS receptors on the cell surface and
244 inhibit LPS signaling. However, even after the removal of LPS, shokyo and kankyo reduced
245 LPS-induced PGE₂ production in the sequential treatment experiment (Figure 2C). If some
246 components in these herbs either competitively or noncompetitively block LPS receptors or
247 reduce PGE₂ production, LPS-induced NF- κ B p65 and ERK phosphorylation should have
248 been inhibited. However, shokyo and kankyo did not suppress LPS-induced NF- κ B and ERK
249 phosphorylation (Figure 3E and 3F). These results therefore excluded this hypothesis, and the
250 target sites of shokyo and kankyo are present intracellularly.

251 Gingerols and shogaols are the major components of ginger (reviewed in Ara et al., 2018);
252 therefore, shokyo and kankyo contain these components. With prolonged storage or heating
253 of ginger, gingerols are dehydrated and converted to shogaols (Afzal et al., 2001). Because
254 kankyo is subjected to heat processing, kankyo contains a larger amount of shogaols than shokyo.
255 Among them, 6-shogaol is one of the bioactive components, and was reported to reduce PGE₂
256 production (Ara et al., 2018). Indeed, kankyo contained 1.7-times the amount of 6-shogaol
257 as shokyo (approximately 60 nM and 100 nM 6-shogaol in 100 $\mu\text{g}/\text{ml}$ of shokyo and kankyo,
258 respectively). Moreover, the effects of kankyo on the reduction of PGE₂ production were greater
259 than those of shokyo (Figure 2D and 2E). Therefore, this difference was considered to be due
260 to the amount of 6-shogaol. However, because shokyo and kankyo are water-extracts of ginger,
261 the amount and effects of gingerols and shogaols are thought to be lower than those of organic
262 solvent-extracts such as methanol.

263 Next, we will discuss the effects of 6-shogaol on PGE₂ production. In this study, the IC₅₀
264 value of 6-shogaol for PGE₂ production was approximately 100 nM (Figure 4A). This IC₅₀ value
265 is consistent with that in previous reports: approximately 100 nM in IL-1 β -treated human oral
266 keratinocytes (Kono et al., 2014) and approximately 60 $\mu\text{g}/\text{ml}$ (= 217 nM) in LPS-treated U937
267 cells (Lantz et al., 2007). However, the IC₅₀ value in this study was considered to be insufficient
268 to inhibit the arachidonic acid cascade, as described below. The IC₅₀ value of 6-shogaol for COX-
269 2 activity is 2.1 μM in A549 cells (Tjendraputra et al., 2001). In another report, 6-shogaol did not
270 inhibit COX-activity in a cell-free experimental model (van Breemen et al., 2011). Although we
271 did not examine the effects of 6-shogaol on COX-2 activity, 100 nM 6-shogaol was considered to

272 not affect COX-2 activity because 100 $\mu\text{g}/\text{ml}$ of kankyo, which contains approximately 100 nM
273 6-shogaol, did not inhibit COX-2 activity. Moreover, 0.17 μM 6-shogaol reduced COX-2 activity
274 to approximately 70 % in IL-1 β -treated human oral keratinocytes (Kono et al., 2014). The
275 reported concentrations of 6-shogaol required for the reduction of COX-2 expression were higher
276 than that in our study. The expression of COX-2 mRNA was reduced to approximately 70 %
277 by 0.17 μM 6-shogaol (Kono et al., 2014). However, the expression of COX-2 protein was not
278 affected by 1 μM 6-shogaol, was slightly reduced by 5 μM , and was significantly reduced by
279 10 μM in LPS-treated mouse microglial BV-2 cells (Ha et al., 2012). Therefore, our results
280 that shokyo and kankyo did not inhibit COX activity are consistent with these previous reports.
281 Similar results were observed in mouse skin (Kim et al., 2005). Similarly, a high concentration
282 of 6-shogaol was reported to be required for the inhibition of NF- κB activation. PMA-induced
283 NF- κB promoter activity was reduced to approximately 50 %, but p65 phosphorylation was not
284 affected by 5 μM shogaol in human breast carcinoma cells (Ling et al., 2010). In this study, even
285 10 μM 6-shogaol did not affect cPLA₂ or COX-2 expression, or NF- κB phosphorylation (Figure
286 4B). Therefore, our results are consistent with these previous results. Our results suggested that
287 6-shogaol reduces LPS-induced PGE₂ production via the inhibition of cPLA₂ activity because
288 the remaining and probable target site in the arachidonic acid cascade is cPLA₂

289 However, the effects of shokyo and kankyo cannot be accounted for by only 6-shogaol.
290 Although 100 $\mu\text{g}/\text{ml}$ of kankyo reduced LPS-induced PGE₂ production to approximately 10 %
291 (Figure 2E), 100 nM 6-shogaol reduced it to approximately 50 % (Figure 4A). Therefore, some
292 components other than 6-shogaol may be involved in the reduction of PGE₂ production. It was
293 previously reported that 6-gingerol is the most abundant in hangeshashinto, which contains
294 kankyo (Kono et al., 2014). Moreover, the amount of 6-shogaol is approximately half of that of
295 6-gingerol, and the amounts of 8-gingerol, 10-gingerol, 8-shogaol, and 10-shogaol are smaller
296 (Kono et al., 2014). 6-Shogaol reduced PGE₂ production the most, followed by 6-gingerol, 8- and
297 10-gingerol, and slight reduction by 8- and 10-shogaol (Kono et al., 2014). Thus, the effects of
298 6-shogaol on the reduction of PGE₂ production are the strongest and those of other components
299 are weak. Therefore, gingerols and shogaols may have additive effects on PGE₂ production.
300 Next, we will discuss the effects of gingerols and shogaols on the arachidonic acid cascade. The
301 IC₅₀ values of these components for the inhibition of COX-2 activity are on the order of μM ,
302 similar to 6-shogaol (Tjendraputra et al., 2001; van Breemen et al., 2011). Moreover, 6-, 8-,
303 and 10-gingerol reduced COX-2 expression at the μM order (Lantz et al., 2007). Among ginger
304 extracts, 10 μM 10-gingerol, 6-shogaol, 8-shogaol, and 10-shogaol reduced cPLA₂ activity to
305 approximately 50 % (Nievergelt et al., 2011). Although the concentrations of these components
306 in shokyo and kankyo are lower than 10 μM , shokyo and kankyo may inhibit cPLA₂ activity by
307 their additive effects.

308 We next evaluated the effects of shokyo and kankyo on the LOX pathway. However,
309 RAW264.7 cells produced only a small amount of LTB₄ regardless of the presence of LPS.
310 Moreover, shokyo and kankyo did not affect LOX-5 expression or LOX activity, suggesting
311 that the LOX pathway is not active in macrophages, and that shokyo and kankyo do not inhibit
312 the lipoxygenase pathway. Aspirin-induced asthma (AIA) is induced by the ingestion of acid
313 nonsteroidal anti-inflammatory drugs (NSAIDs), and is considered to be caused by leukotrienes,
314 which are increased by acid NSAIDs and contract the bronchus (Vaszar and Stevenson, 2001;
315 Bochenek et al., 2002). Similarly, acid NSAIDs exacerbate general asthma. Based on our
316 findings that (1) shokyo and kankyo inhibit upstream of the arachidonic acid cascade, (2) they
317 did not inhibit the cyclooxygenase pathway, and (3) they did not enhance lipoxygenase pathways,
318 shokyo and kankyo may reduce leukotriene production. Therefore, shokyo and kankyo may not
319 exacerbate asthma, including AIA. As such, shokyo and kankyo may be safely used for patients
320 with asthma, including AIA, instead of conventional anti-inflammatory drugs. Moreover, as

321 oral-administrated ginger protected aspirin-induced gastric ulcers in rats (Wang et al., 2011),
322 shokyo and kankyo may be available as anti-inflammatory drugs instead of NSAIDs.

323 CONCLUSION

324 We demonstrated that shokyo and kankyo, which are water-extracted fractions of ginger, reduced
325 LPS-induced PGE₂ production in RAW264.7 cells. Their mechanisms of action were suggested
326 to via the inhibition of cPLA₂ activity because both herbs did not inhibit COX activity or suppress
327 the expression of molecules in the arachidonic acid cascade.

328 ACKNOWLEDGMENTS

329 We thank Prof. Nobuyuki Udagawa (Department of Biochemistry, Matsumoto Dental University)
330 and Prof. Naoyuki Takahashi (Institute for Oral Science, Matsumoto Dental University) for their
331 advice on our study.

332 REFERENCES

- 333 Afzal, M., Al-Hadidi, D., Menon, M., Pesek, J., and Dhami, M. (2001). Ginger: an ethnomedical,
334 chemical and pharmacological review. *Drug Metabol Drug Interact*, 18(3-4):159–190.
- 335 Aimbire, F., Penna, S., Rodrigues, M., Rodrigues, K., Lopes-Martins, R., and Sertié, J. (2007).
336 Effect of hydroalcoholic extract of *Zingiber officinalis* rhizomes on LPS-induced rat airway
337 hyperreactivity and lung inflammation. *Prostaglandins Leukot Essent Fatty Acids*, 77(3-
338 4):129–138.
- 339 Ara, T., Honjo, K., Fujinami, Y., Hattori, T., Imamura, Y., and Wang, P. (2010). Preventive
340 effects of a kampo medicine, orento on inflammatory responses in lipopolysaccharide treated
341 human gingival fibroblasts. *Biol Pharm Bull*, 33(4):611–616.
- 342 Ara, T., Maeda, Y., Fujinami, Y., Imamura, Y., Hattori, T., and Wang, P. (2008). Preventive
343 effects of a kampo medicine, shosaikoto, on inflammatory responses in LPS-treated human
344 gingival fibroblasts. *Biol Pharm Bull*, 31(6):1141–1144.
- 345 Ara, T., Nakatani, S., Kobata, K., Sogawa, N., and Sogawa, C. (2018). The biological efficacy of
346 natural products against acute and chronic inflammatory diseases in the oral region. *Medicines*
347 (*Basel*), 5(4):122.
- 348 Ara, T. and Sogawa, N. (2016). Studies on shokyo, kanzo, and keihi in kakkonto medicine on
349 prostaglandin E₂ production in lipopolysaccharide-treated human gingival fibroblasts. *Int Sch*
350 *Res Notices*, 2016:9351787.
- 351 Ara, T. and Sogawa, N. (2017). Effects of shinbuto and ninjinto on prostaglandin E₂ production
352 in lipopolysaccharide-treated human gingival fibroblasts. *PeerJ*, 5:e4120.
- 353 Bochenek, G., Bánska, K., Szabó, Z., Nizankowska, E., and Szczeklik, A. (2002). Diagnosis,
354 prevention and treatment of aspirin-induced asthma and rhinitis. *Curr Drug Targets Inflamm*
355 *Allergy*, 1(1):1–11.
- 356 El-Abhar, H., Hammad, L., and Gawad, H. (2008). Modulating effect of ginger extract on rats
357 with ulcerative colitis. *J Ethnopharmacol*, 118(3):367–372.
- 358 Gijón, M., Spencer, D., Kaiser, A., and Leslie, C. (1999). Role of phosphorylation sites and the
359 C2 domain in regulation of cytosolic phospholipase A₂. *J Cell Biol*, 145(6):1219–1232.
- 360 Gupta, C., Katsumata, M., Goldman, A., Herold, R., and Piddington, R. (1984). Glucocorticoid-
361 induced phospholipase A₂-inhibitory proteins mediate glucocorticoid teratogenicity *in vitro*.
362 *Proc Natl Acad Sci U S A*, 81(4):1140–1143.
- 363 Ha, S., Moon, E., Ju, M., Kim, D., Ryu, J., Oh, M., and Kim, S. (2012). 6-shogaol, a ginger prod-
364 uct, modulates neuroinflammation: a new approach to neuroprotection. *Neuropharmacology*,
365 63(2):211–223.

- 366 Hothorn, T., Bretz, F., and Westfall, P. (2008). Simultaneous Inference in General Parametric
367 Models. *Biom J*, 50(3):346–363.
- 368 Kim, S., Kundu, J., Shin, Y., Park, J., Cho, M., Kim, T., and Surh, Y. (2005). [6]-gingerol inhibits
369 COX-2 expression by blocking the activation of p38 MAP kinase and NF- κ B in phorbol
370 ester-stimulated mouse skin. *Oncogene*, 24(15):2558–2567.
- 371 Kitamura, H., Urano, H., and Ara, T. (2014). Preventive effects of a kampo medicine, kakkonto,
372 on inflammatory responses via the suppression of extracellular signal-regulated kinase phos-
373 phosphorylation in lipopolysaccharide-treated human gingival fibroblasts. *ISRN Pharmacol*,
374 2014:784019.
- 375 Kono, T., Kaneko, A., Matsumoto, C., Miyagi, C., Ohbuchi, K., Mizuhara, Y., Miyano, K., and
376 Uezono, Y. (2014). Multitargeted effects of hangeshashinto for treatment of chemotherapy-
377 induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes.
378 *Integr Cancer Ther*, 13(5):435–445.
- 379 Lakhan, S., Ford, C., and Tepper, D. (2015). *Zingiberaceae* extracts for pain: a systematic review
380 and meta-analysis. *Nutr J*, 14:50.
- 381 Lantz, R., Chen, G., Sarihan, M., Solyom, A., Jolad, S., and Timmermann, B. (2007). The
382 effect of extracts from ginger rhizome on inflammatory mediator production. *Phytotherapy*,
383 14(2-3):123–128.
- 384 Lin, L., Wartmann, M., Lin, A., Knopf, J., Seth, A., and Davis, R. (1993). cPLA₂ is phosphory-
385 lated and activated by MAP kinase. *Cell*, 72(2):269–278.
- 386 Ling, H., Yang, H., Tan, S., Chui, W., and Chew, E. (2010). 6-Shogaol, an active constituent of
387 ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression
388 via blockade of nuclear factor- κ B activation. *Br J Pharmacol*, 161(1):1763–1777.
- 389 Nakazono, Y., Ara, T., Fujinami, Y., Hattori, T., and Wang, P. (2010). Preventive effects of a
390 kampo medicine, hangeshashinto on inflammatory responses in lipopolysaccharide-treated
391 human gingival fibroblasts. *J Hard Tissue Biol*, 19(1):43–50.
- 392 Nievergelt, A., Marazzi, J., Schoop, R., Altmann, K., and Gertsch, J. (2011). Ginger phenyl-
393 propanoids inhibit IL-1 β and prostanoid secretion and disrupt arachidonate-phospholipid
394 remodeling by targeting phospholipases A₂. *J Immunol*, 187(8):4140–4150.
- 395 R Development Core Team (2018). R: A Language and Environment for Statistical Computing.
- 396 Ritz, C., Baty, F., Streibig, J., and Gerhard, D. (2015). Dose-response analysis using R. *PLOS*
397 *ONE*, 10(e0146021).
- 398 Thomson, M., Al-Qattan, K., Al-Sawan, S., Alnaqeeb, M., Khan, I., and Ali, M. (2002). The
399 use of ginger (*Zingiber officinale* Rosc.) as a potential anti-inflammatory and antithrombotic
400 agent. *Prostaglandins Leukot Essent Fatty Acids*, 67(6):475–478.
- 401 Tjendraputra, E., Tran, V., Liu-Brennan, D., Roufogalis, B., and Duke, C. (2001). Effect of ginger
402 constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. *Bioorg*
403 *Chem*, 29(3):156–163.
- 404 van Breemen, R., Tao, Y., and Li, W. (2011). Cyclooxygenase-2 inhibitors in ginger (*Zingiber*
405 *officinale*). *Fitoterapia*, 82(1):38–43.
- 406 Vaszar, L. and Stevenson, D. (2001). Aspirin-induced asthma. *Clin Rev Allergy Immunol*,
407 21(1):71–87.
- 408 Wallner, B., Mattaliano, R., Hession, C., Cate, R., Tizard, R., Sinclair, L., Foeller, C., Chow, E.,
409 Browning, J., Ramachandran, K., and Pepinsky, R. (1986). Cloning and expression of human
410 lipocortin, a phospholipase A₂ inhibitor with potential anti-inflammatory activity. *Nature*,
411 320(6057):77–81.
- 412 Wang, Z., Hasegawa, J., Wang, X., Matsuda, A., Tokuda, T., Miura, N., and Watanabe, T. (2011).
413 Protective effects of ginger against aspirin-induced gastric ulcers in rats. *Yonago Acta Med*,
414 54(1):11–19.

415 Wilborn, J., Crofford, L., Burdick, M., Kunkel, S., Strieter, R., and Peters-Golden, M. (1995).
416 Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a
417 diminished capacity to synthesize prostaglandin E₂ and to express cyclooxygenase-2. *J Clin*
418 *Invest*, 95(4):1861–1868.

Table 1. Concentrations of 6-shogaol in shokyo and kankyo by HPLC analysis

	concentration of herb	
	5 mg/ml	100 µg/ml
shokyo	2.97 µM	59.4 µM
kankyo	4.87 µM	97.4 µM

Chromatography profiles are shown in Supplemental Figure 2

419 FIGURE LEGENDS

420 Figure 1

421 Cytotoxicity of shokyo (A) and kankyo (B). RAW264.7 cells were treated with each herb (0,
422 100, 300, or 1000 µg/ml) for 24 h. Then, the numbers of viable cells were measured by WST-8.
423 *P*-values vs. without each herb were calculated by Dunnett's method. **P* < 0.05, ****P* < 0.001.

424 Figure 2

425 Effects of shokyo and kankyo on PGE₂ production. (A) Time schedule of treatment with LPS
426 and/or each herb. Simultaneous treatment: Cells were treated with combinations of LPS (0
427 or 100 ng/ml) and medium or each herb (100 µg/ml) for 24 h. Sequential treatment: Cells
428 were treated with medium or LPS (100 ng/ml) for 30 min, washed, and further treated with
429 medium or each herb (100 µg/ml) for 24 h. (B, C) Concentrations of PGE₂ were measured
430 by ELISA, adjusted by cell number, and expressed as per 10000 cells (mean ± SD, n = 3) in
431 simultaneous (B) and sequential (C) treatment experiments. med: medium, s: shokyo, k: kankyo.
432 (D, E) Concentration-dependent effects of shokyo (D) and kankyo (E) on LPS-induced PGE₂
433 production. Cells were treated with combinations of LPS (100 ng/ml) and each herb (0, 1, 10,
434 or 100 µg/ml) for 24 h. *P*-values vs. with LPS alone were calculated by Dunnett's method.
435 **P* < 0.05, ***P* < 0.01, ****P* < 0.001.

436 Figure 3

437 Effects of shokyo and kankyo on the arachidonic acid cascade and intracellular signal trans-
438 duction. (A) Time schedule of treatment with LPS and/or each herb. Simultaneous treatment:
439 RAW264.7 cells were treated with LPS (100 ng/ml) and medium or each herb (100 µg/ml) for
440 6 h, washed, and then treated with 10 µM arachidonic acid for 30 min. Sequential treatment:
441 RAW264.7 cells were treated with LPS (100 ng/ml) for 6 h, and further treated with medium or
442 each herb (100 µg/ml) for 1 h. Then, the cells were washed and treated with 10 µM arachidonic
443 acid for 30 min. (B, C) Effects of shokyo and kankyo on COX activity. Concentrations of PGE₂
444 were measured by ELISA, adjusted by cell number, and expressed as per 10000 cells (mean ±
445 SD, n = 4) in simultaneous (B) and sequential (C) treatment experiments. *P*-values vs. with LPS
446 alone by Dunnett's test are indicated. (D) Effects of herbs on cPLA₂, annexin 1, and COX-2
447 expression. RAW264.7 cells were treated with a combination of LPS (0 or 100 ng/ml) and
448 medium or each herb (100 µg/ml) for 8 h, and protein levels were examined by Western blotting.
449 (E, F) Effects of herbs on NF-κB and ERK phosphorylation. RAW264.7 cells were treated with
450 each herb (100 µg/ml) for 1 h and further treated with LPS (100 ng/ml) for 15 min. NF-κB p65
451 and phosphorylated p65 levels (E), and ERK and phosphorylated ERK (pERK) levels (F) were
452 examined by Western blotting. The upper band indicates ERK1 (p44 MAPK) and the lower band
453 indicates ERK2 (p42 MAPK) in (F). med: medium, s: shokyo, k: kankyo.

454 Figure 4

455 Effects of 6-shogaol on LPS-induced PGE₂, the arachidonic acid cascade, and intracellular
456 signal transduction. (A) Effects of 6-shogaol on LPS-induced PGE₂, RAW264.7 cells were
457 treated with LPS (100 ng/ml) and each herb (100 µg/ml) for 24 h. Concentrations of PGE₂ were
458 measured by ELISA, adjusted by cell number, and expressed as per 10000 cells (mean ± SD, n
459 = 3). *P*-values vs. with LPS alone were calculated by Dunnett's method. **P* < 0.05, ***P* < 0.01,
460 ****P* < 0.001. Red and blue lines represent the effects of shokyo and kankyo in Figure 2D and
461 2E, respectively. The concentrations of 6-shogaol were calculated using the results shown in
462 Table 1. (B) Effects of 6-shogaol on cPLA₂, annexin 1, and COX-2 expression. RAW264.7 cells
463 were treated with a combination of LPS (0 or 100 ng/ml) and 6-shogaol (0, 0.1, 1, or 10 µM)
464 for 8 h, and protein levels were examined by Western blotting. (C, D) Effects of 6-shogaol on
465 NF-κB and ERK phosphorylation. RAW264.7 cells were treated with 6-shogaol (0, 0.1, 1, or 10
466 µM) for 1 h and further treated with LPS (100 ng/ml) for 15 min. NF-κB p65/phosphorylated
467 p65 levels (C), and ERK/phosphorylated ERK (pERK) levels (D) were examined by Western
468 blotting.




Figure 1. Cytotoxicity of shokyo and kankyo




Figure 2. Effects of shokyo and kankyo on PGE₂ production




Figure 3. Effects of shokyo and kankyo on the arachidonic acid cascade and intracellular signal transduction




Figure 4. Effects of 6-shogaol on LPS-induced PGE₂, the arachidonic acid cascade, and intracellular signal transduction